PDCD1 and Miyoshi myopathy: Immune checkpoint inhibitor, Nivolumab, which is a CD279 inhibitor did not produce a favorable therapeutic response in phase I trials which indicate that the spectrum of anti-tumor T cell response in MM still needs to be thoroughly understood [13].